Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

21 January 2020

Das Versagen der Pharmariesen im Kampf gegen die Super-Erreger

Anja Ettel covers the new Antimicrobial Resistance Benchmark for Die Welt, highlighting the risky withdrawal of pharma companies from the antibiotic market.

Direct links

Read the full article

The articles describes today's fragile antibiotic market, where large and prominent drugmakers have retreated from the antibiotics field and smaller innovative biotech companies have gone bankrupt due to the poor financial rewards on offer.

Drawing from the results of the Benchmark, the author looks at where progress is being made by pharma companies, even though the market is failing. Jayasree Iyer, Executive Director of the Access to Medicine Foundation, is featured in the article:

“The threat of drug resistance is still not being addressed to the extent necessary. And with the withdrawal of companies from the research and manufacture of antibiotics, the infrastructure of this market is becoming increasingly decentralized and holey, and the hurdles for market entry and supply are increasing."

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved